Friday, January 05, 2018 10:15 PM ET
Significant Insider Selling Continues at Biohaven Pharmaceutical Holding (BHVN)
A filing with the SEC today disclosed a substantial insider sale of Biohaven Pharmaceutical Holding shares as — Gregory Bailey, Director — sold 50,000 shares in the company having a market value of approximately $1,435,528. There have been 4 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the sale of 424,600 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 474,600 shares and have averaged 94,920 shares per transaction over this time period.
The number of insider buy/sell trades at Biohaven Pharmaceutical Holding is greater than that of the 190 peer company average over the last 90-day period. The Biotechnology & Medical Research peer group saw 160 buy/sell trades during this period for an average of 0.8 transactions per company. However, the number of shares traded per transaction by Biohaven Pharmaceutical Holding insiders is lower than its peers. Within the peer group there were 26,685,061 shares purchased and 11,325,839 shares sold with company insiders having bought 127,994 shares on average over this time period.
In order to focus on significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated data sourced to evaluate and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2018 UpTick Data Technologies. All rights reserved.